Genetic variability in the receptors for GLP-1 (GLP-1R rs10305420, GLP-1R rs6923761) and GIP (GIPR rs1800437) has been associated with increased odds of AD and PD while correlating with elevated disease biomarkers (ie, amyloid-beta (A) peptide 42, tau proteins clustered in neurofibrillary tangles (NFT)) measured in the cerebrospinal fluid (CSF).19 A Mendelian randomisation study from the UK Biobank data found an association between genetic variants coding for GLP-1RAs and a lower risk of ADalthough these results must be interpreted cautiously as the study failed to show the expected associations with weight loss used as a positive control.18 Low levels of GLP-1 in serum were suggestive of higher odds of mild cognitive impairment (MCI) in a small sample of 106 patients with T2DM.21 More recently, a major study on the effects of the GLP-1RA semaglutide on the circulating proteome of some 2000 participants with overweight or obesity plus or minus diabetes from two phase III trials (STEP 1 and STEP 2) has identified two significantly regulated proteins, namely tenascin-C and progranulin, that are implicated in AD neuropathology.20 From a mechanistic perspective, however, most evidence regarding the putative neuroprotective activity of GLP-1RAs stems from preclinical, that is, in vitro or animal models.10 17 In summary, beyond peripheral glycaemic control, GLP-1RAs display broad actions against neurodegeneration and ageing processes while being capable of enhancing cognitive abilities

Stronger GH pulse Complementary action amplifies GH release
Women of childbearing potential should use reliable contraception if they receive GLP-1 agonists, given the potential risks to fetal development (48)
You need two or three safe options that do not make the day harder
Deacon, C